Published in Nursing Home and Elder Business Week, June 19th, 2005
The U.S. Food and Drug Administration approved Mycamine in March 2005 for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and the treatment of esophageal candidiasis.
Mycamine is the first product to be launched by Astellas Pharma U.S., Inc., which was recently formed through the merger of Fujisawa Healthcare, Inc., and Yamanouchi Pharma America, Inc.
"The launch and availability of Mycamine, an important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Nursing Home and Elder Business Week